Renal cell carcinoma accounts for 3% of all malignant tumors.
Until a few years ago, immunotherapy (Interferon and/or Interleukin-2) was the only approved systemic treatment in the metastatic setting. Better knowledge of renal cell cancer biology drew attention on the fundamental role of angiogenesis. Several strategies targeting angiogenesis have been developed including VEGF and VEGFR inhibitors. They are now the standard treatment in first and second line. Pazopanib, a VEGFR tyrosine kinase inhibitor, is one of the treatment options recommended for patients with metastatic renal cell carcinoma, in first line and after cytokines failure. Since more recently, pazopanib is also approved in the treatment of metastatic soft tissue sarcoma, after failure of at least one line of chemoterapy. In this paper, we will review the mechanism of action and the clinical results of pazopanib in renal cell carcinoma and sarcoma.
Written by:
Gennigens C, Jerusalem G. Are you the author?
Chargé de Cours, Service d'Oncologie médicale, CHU de Liège.
Reference: Rev Med Liege. 2012 Jul-Aug;67(7-8):437-42.
PubMed Abstract
PMID: 22984765
Article in French.
UroToday.com Renal Cancer Section
